Oxford Cannabinoid - Directors’ Dealings

RNS Number : 4819E

Oxford Cannabinoid Tech.Holdings

26 February 2024

Oxford Cannabinoid Technologies Holdings plc

("OCT" or the "Company")

Directors' Dealings

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, announces that it has been informed that Clarissa Sowemimo-Coker, the Chief Executive Officer of the Company, and Julie Pomeroy, the Company's Non-Executive Chair, have today purchased ordinary shares of £0.001 ("Ordinary Shares") in the Company.

Director	Total number of Ordinary Shares purchased	Price per Ordinary Share	Number of Ordinary Shares held following the purchase
Clarissa Sowemimo-Coker	1,000,000	£0.0045	2,500,000
Julie Pomeroy	450,000	£0.004575	650,000

Clarissa Sowemimo-Coker, Chief Executive Officer of OCT, said:

"Today marks further evidence of the management's support of OCT, following our participation in a successful fundraise in January 2024 where we also welcomed Cantheon Capital LLC as a cornerstone investor of the Company. Both I and OCT's chair, Julie Pomeroy, have increased our personal shareholdings in OCT, demonstrating our commitment to the business and our resolute belief in the Company's future pipeline. I look forward to continuing to work with colleagues to deliver further for our shareholders with the ultimate aim of helping people living with debilitating conditions."

The PDMR forms are set out below.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company take responsibility for this announcement.

Enquiries:

Oxford Cannabinoid Technologies Holdings plc	+44 (0)20 3034 2820
Clarissa Sowemimo-Coker (CEO)	clarissa@oxcantech.com

Cairn Financial Advisers LLP
Emily Staples	+44 (0)20 7213 0897
Jo Turner	+44 (0) 20 7213 0885

Axis Capital Markets Limited
Richard Hutchison	+44 (0)20 3026 0320

Acuitas Communications	020 3745 0293 / 07799 767676
Simon Nayyar	simon.nayyar@acuitascomms.com
Arthur Dingemans	arthur.dingemans@acuitascomms.com

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCT") is the holding company of Oxford Cannabinoid Technologies Ltd and OCT Victoria Pty Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines initially targeting the US$ multi-billion global pain market.

OCT currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently forecast to reach US$1.17bn by 2028.

OCT's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive licence agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCT now has a portfolio of almost five hundred derivatives and intellectual property rights including fourteen patent families and associated research data.

OCT has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCT's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Clarissa Sowemimo-Coker
2	Reason for notification
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Cannabinoid Technologies Holdings plc
b.	LEI	2138005SRWT4998BCE35
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.001 each GB00BMVMRB86
b.	Nature of the transaction	Acquisition of ordinary shares of £0.001 each
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.0045	1,000,000

d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	26 February 2024
f.	Place of the transaction	London, UK
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Julie Pomeroy
2	Reason for notification
a.	Position/Status	Non-Executive Chair
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Cannabinoid Technologies Holdings plc
b.	LEI	2138005SRWT4998BCE35
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.001 each GB00BMVMRB86
b.	Nature of the transaction	Acquisition of ordinary shares of £0.001 each
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.004575	450,000

d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	26 February 2024
f.	Place of the transaction	London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGZGZZFVDGDZM]]>